Exclusive Agreement Reached for Golimumab Biosimilar in EU and UK

Tuesday, 28 May 2024, 12:40

Bio-Thera and STADA have entered into an exclusive agreement for BAT2506, a proposed biosimilar of Golimumab, in the European Union and the United Kingdom. This collaboration aims to bring a new treatment option to patients while expanding market presence for both companies. The agreement signifies a strategic move to strengthen their positions in the biosimilars market with potential benefits for stakeholders and patients alike.

https://store.livarava.com/c095a5e7-1d0a-11ef-a3dc-9d5fa15a64d8.jpg — Exclusive Agreement Reached for Golimumab Biosimilar in EU and UK

Exclusive Agreement for Golimumab Biosimilar

Bio-Thera and STADA have reached an exclusive agreement for BAT2506, a proposed biosimilar of Golimumab, for the European Union and the United Kingdom.

Key Points:

Partnership: Bio-Thera and STADA collaborate to introduce a new biosimilar treatment.
Market Expansion: The agreement aims to expand market presence and offerings in the biosimilars sector.
Strategic Move: Strengthening positions in the biosimilars market can bring benefits to stakeholders and patients.

The partnership between Bio-Thera and STADA for BAT2506 signifies a significant step towards providing a competitive biosimilar option in the EU and UK.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.